Keloid Scarring: Treatment and Pathophysiology

• Status: Unknown status
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To clarify the mechanisms of Keloid scar formation.

Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment

Identify the genetic link with Keloid scar formation.

Quantify the psychological/social impact in keloid scarring patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Queen Mary University of London
• Treatments: Fluorouracil; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Adult ( > 18 years old).

• Keloid scarring present.

• Able to understand and give informed consent.

• Patients giving informed consent to donate keloidal or non-affected skin when that is redundant after a procedure (i.e. BBR, Abdominoplasty).

• Patients with a strong familial pedigree of keloid scar formation.

Exclusion Criteria:

• Open wound at or proximity of the lesion

• Infected lesion

• Pregnant or planning pregnancy in the near future

• Lactating (Breast Feeding)

• Abnormal renal or liver function tests

• Atrophic scars

• Patient under 18 years of age

• Immunocompromised

• OR immunosuppressed